Share on StockTwits

Research analysts at Laidlaw initiated coverage on shares of Mast Therapeutics (NASDAQ:MSTX) in a report released on Wednesday. The firm set a “buy” rating and a $2.50 price target on the stock. Laidlaw’s price target suggests a potential upside of 318.34% from the company’s current price.

Separately, analysts at ISI Group initiated coverage on shares of Mast Therapeutics in a research note on Monday, June 16th. They set a “reduce” rating on the stock.

Mast Therapeutics (NASDAQ:MSTX) traded up 6.71% during mid-day trading on Wednesday, hitting $0.5976. The stock had a trading volume of 1,225,523 shares. Mast Therapeutics has a 52 week low of $0.40 and a 52 week high of $1.10. The stock’s 50-day moving average is $0.61 and its 200-day moving average is $0.68. The company’s market cap is $68.2 million.

Mast Therapeutics, Inc, formerly ADVENTRX Pharmaceuticals, Inc, is a development-stage company biopharmaceutical company focused on developing product candidates.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.